Clinical Trial

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being done to answer the following question: Can testing breast cancer for DNA abnormalities or "biomarkers" help predict which patients are most likely to be helped by certain treatments? The pre-study screening is being done to test a sample of blood (or tumour tissue) for biomarkers to see if patients can participate in the study
Protocol Amendment History 23 amendments
This ClinicalTrials.gov record has been amended 23 times since 2022-10-28; most recent amendment 2026-05-06.
Status change: Not Yet Recruiting → Recruiting 2023-02-06
Trial Details
NCT Number NCT05601440
Lead Sponsor Canadian Cancer Trials Group
Conditions Breast Cancer
Enrollment 484 participants
Start Date 2023-06-13
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-07